Article

ImmusanT (NEXPEP) present results of Phase 1 Coeliac vaccine

May 8, 2011

Bob Anderson (CEO Nexpep Pty Ltd), CSO ImmusanT Inc., discussed the results of phase 1 Nexvax2 study at the recent Digestive Diseases Week conference in Chicago, Illinois. For the study Medicines Development provided a full time Development Manager and a part time Project Leader to supplement Nexpep’s own internal resources.

Watch on YouTube.

REFERENCES

Stay up to date

Follow our work by signing up for our newsletter

Thank you, your submission has been received.
Oops! Something went wrong while submitting the form.